Sriparna Roy

India

Correspondent at Reuters

Actress of Star Jalsha (Tollywood)

Featured in: Favicon

reuters.com (+1) Favicon

uol.com.br Favicon

msn.com

terra.com.br Favicon

usatoday.com Favicon

yahoo.com (+14) Favicon

indiatimes.com Favicon

aol.com

ibtimes.com Favicon

theglobeandmail.com + 90 more

Articles

UnitedHealth CEO leaves abruptly, company pulls forecast as shares sink

2 days ago | ca.marketscreener.com | Sriparna Roy |Sneha K

(Reuters) - UnitedHealth Group Chief Executive Andrew Witty stepped down suddenly on Tuesday, the company said, as it suspended its 2025 forecast due to surging medical costs, sending its shares plunging more than 11% in morning trading. Former CEO Stephen Hemsley, who has been with the healthcare conglomerate for 28 years, is returning to the top role after stepping down in 2017. Witty chose to leave for personal reasons, the company said, without elaborating.
UnitedHealth CEO leaves abruptly, company pulls forecast as shares sink

2 days ago | finance.yahoo.com | Sriparna Roy |Sneha K

By Sriparna Roy and Sneha S K (Reuters) - UnitedHealth Group said its Chief Executive Andrew Witty resigned as of Tuesday, and the company suspended its annual forecast due to surging medical costs, sending shares plunging over 15% to a four-year low. Chairman Stephen Helmsley, 72, who was CEO before stepping down in 2017, will assume the CEO title once again. Witty chose to leave for personal reasons, the company said, without elaborating.
UnitedHealth CEO leaves abruptly, company pulls forecast as shares sink

2 days ago | gazette.com | Sriparna Roy |Sneha K

By Sriparna Roy and Sneha S K(Reuters) - UnitedHealth Group Chief Executive Andrew Witty stepped down suddenly on Tuesday, the company said, as it suspended its 2025 forecast due to surging medical costs, sending its shares plunging more than 11% in morning trading. Former CEO Stephen Hemsley, who has been with the healthcare conglomerate for 28 years, is returning to the top role after stepping down in 2017. Witty chose to leave for personal reasons, the company said, without elaborating.
Pharma stocks recover from initial shock of Trump's drug pricing order

3 days ago | marketscreener.com | Sriparna Roy |Joel Jose

(Reuters) -Shares of U.S. drugmakers rebounded on Monday after an initial selloff as analysts said that President Donald Trump's sweeping executive order to slash prescription drug prices would be difficult to implement and face legal challenges. Trump signed a wide-reaching executive order on Monday directing drugmakers to lower the prices of their medicines to align with what other countries pay.
Pharma stocks recover from initial shock of Trump's drug pricing order

3 days ago | sg.finance.yahoo.com | Sriparna Roy |Joel Jose

By Sriparna Roy and Joel Jose (Reuters) -Shares of U.S. drugmakers rebounded on Monday after an initial selloff as analysts said that President Donald Trump's sweeping executive order to slash prescription drug prices would be difficult to implement and face legal challenges. Trump signed a wide-reaching executive order on Monday directing drugmakers to lower the prices of their medicines to align with what other countries pay.
US FDA permits use of three natural-source colors in food items

4 days ago | ksl.com | Sriparna Roy

WHITE OAK, Md. — The U.S. Food and Drug Administration said on Friday that it had granted permissions to three new color additives, marking them as safe to use in food products and expanding the range of natural-source colors available to manufacturers. Health Secretary Robert F.
米ノババックス、第1四半期はコスト削減で黒字転換

6 days ago | jp.reuters.com | Sriparna Roy

米バイオ医薬品会社ノババックスが８日発表した第１・四半期決算は、純損益が前年同期の１億４８００万ドルの赤字から、５億１９００万ドルの黒字に転換した。新型コロナウイルスワクチンの開発・販売に関連するコスト削減が利益を押し上げた。写真は同社のロゴと注射器。２０２１年１１月撮影（２０２５年ロイター/Dado Ruvic） [８日ロイター] - 米バイオ医薬品会社ノババックス(NVAX.O), opens new tabが８日発表した第１・四半期決算は、純損益が前年同期の１億４８００万ドルの赤字から、５億１９００万ドルの黒字に転換した。新型コロナウイルスワクチンの開発・販売に関連するコスト削減が利益を押し上げた。売上高は前年同期の９４００万ドルから６億６７００万ドルに増加し、ＬＳＥＧがまとめたアナリスト予想平均の３億４３８５万ドルを大幅に上回った。増収の主な要因は、カナダとニュージーランドとの購入契約終了に伴い、６億０３００万ドルの売り上げが認識されたことと、過年度の現金受領など。...
Novavax says talks with FDA on COVID vaccine approval ongoing calming investor fears

6 days ago | finance.yahoo.com | Sriparna Roy

By Sriparna Roy (Reuters) -Novavax on Thursday tried to calm investors spooked by the delay of full approval of its COVID vaccine shot by U.S. regulators saying that it sees a pathway to resolving issues with the FDA, sending shares up nearly 19% in early trading. The vaccine maker said it believes commitments to run new trials would be after it receives approval for the shot. "Based on what we've received to date, formally from FDA, they're asking for a post-marketing commitment.
Novavax says talks with FDA on COVID vaccine approval ongoing calming investor fears

1 week ago | marketscreener.com | Sriparna Roy

(Reuters) -Novavax on Thursday tried to calm investors spooked by the delay of full approval of its COVID vaccine shot by U.S. regulators saying that it sees a pathway to resolving issues with the FDA, sending shares up nearly 19% in early trading. The vaccine maker said it believes commitments to run new trials would be after it receives approval for the shot. "Based on what we've received to date, formally from FDA, they're asking for a post-marketing commitment.
Novavax says talks with FDA on COVID vaccine approval ongoing calming investor fears

1 week ago | today.westlaw.com | Sriparna Roy |Alexandra Hudson |Shailesh Kuber

(Reuters) -Novavax on Thursday tried to calm investors spooked by the delay of full approval of its COVID vaccine shot by U.S. regulators saying that it sees a pathway to resolving issues with the FDA, sending shares up nearly 19% in early trading....